Tobias Bexte
@bextetobias.bsky.social
Physician | Scientist | Immunotherapies | NK cells | Gene-editing
Frankfurt am Main
https://www.linkedin.com/in/tobias-bexte-76643b124/
Frankfurt am Main
https://www.linkedin.com/in/tobias-bexte-76643b124/
Reposted by Tobias Bexte
BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 (thread 👇)
October 15, 2025 at 12:22 PM
BIG ANNOUNCEMENT📣: I haven’t been this excited to be part of something new in 15 years… Thrilled to reveal the passion project I’ve been working on for the past year and a half!🙀🥳 (thread 👇)
Reposted by Tobias Bexte
@dlwagnerlabs.bsky.social on tour! 🌍🇩🇪🇺🇸
We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸
Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸
Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
October 12, 2025 at 1:45 PM
@dlwagnerlabs.bsky.social on tour! 🌍🇩🇪🇺🇸
We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸
Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸
Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
🚨 Paper alert!
"Next-gen multiplex-edited CAR-NK cells: more edits, more power?" @jitc @bmj.com
With @dlwagner.bsky.social we discuss Wang et al.’s landmark paper on multiplex base-edited non-viral CAR-NK cells. Promising efficiency but safety challenges! jitc.bmj.com/content/13/9...
"Next-gen multiplex-edited CAR-NK cells: more edits, more power?" @jitc @bmj.com
With @dlwagner.bsky.social we discuss Wang et al.’s landmark paper on multiplex base-edited non-viral CAR-NK cells. Promising efficiency but safety challenges! jitc.bmj.com/content/13/9...
Next-generation multiplex-edited CAR-NK cells: more edits, more power?
First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ c...
jitc.bmj.com
September 17, 2025 at 9:44 PM
🚨 Paper alert!
"Next-gen multiplex-edited CAR-NK cells: more edits, more power?" @jitc @bmj.com
With @dlwagner.bsky.social we discuss Wang et al.’s landmark paper on multiplex base-edited non-viral CAR-NK cells. Promising efficiency but safety challenges! jitc.bmj.com/content/13/9...
"Next-gen multiplex-edited CAR-NK cells: more edits, more power?" @jitc @bmj.com
With @dlwagner.bsky.social we discuss Wang et al.’s landmark paper on multiplex base-edited non-viral CAR-NK cells. Promising efficiency but safety challenges! jitc.bmj.com/content/13/9...
🥳 #PaperAlert 🚨
Huge congrats to my lab-bestie Lisa Marie Reindl!! 💪🎉 So proud of you!😎🌟
EGFR-tarheting CAR NKcells in combination with radiotherapy showed significant tumor reduction ex vivo and in vivo in hard-to-treat solid tumors of rhabdomyosarcoma!
jitc.bmj.com/content/13/7... @bmj.com
Huge congrats to my lab-bestie Lisa Marie Reindl!! 💪🎉 So proud of you!😎🌟
EGFR-tarheting CAR NKcells in combination with radiotherapy showed significant tumor reduction ex vivo and in vivo in hard-to-treat solid tumors of rhabdomyosarcoma!
jitc.bmj.com/content/13/7... @bmj.com
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy
Background: Rhabdomyosarcoma (RMS) is the most common type of soft-tissue sarcoma in children, and it remains a challenging cancer with poor outcomes in high-risk and metastatic patients. This study r...
jitc.bmj.com
July 8, 2025 at 1:35 PM
🥳 #PaperAlert 🚨
Huge congrats to my lab-bestie Lisa Marie Reindl!! 💪🎉 So proud of you!😎🌟
EGFR-tarheting CAR NKcells in combination with radiotherapy showed significant tumor reduction ex vivo and in vivo in hard-to-treat solid tumors of rhabdomyosarcoma!
jitc.bmj.com/content/13/7... @bmj.com
Huge congrats to my lab-bestie Lisa Marie Reindl!! 💪🎉 So proud of you!😎🌟
EGFR-tarheting CAR NKcells in combination with radiotherapy showed significant tumor reduction ex vivo and in vivo in hard-to-treat solid tumors of rhabdomyosarcoma!
jitc.bmj.com/content/13/7... @bmj.com